Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

5-Aza-4′-thio-2′-deoxycytidine, a New Orally Bioavailable Nontoxic “Best-in-Class”: DNA Methyltransferase 1–Depleting Agent in Clinical Development

Journal of Pharmacology and Experimental Therapeutics(2021)10.1124/jpet.121.000758Source: DataRank Database

5-Aza-4′-thio-2′-deoxycytidine, a New Orally Bioavailable Nontoxic “Best-in-Class”: DNA Methyltransferase 1–Depleting Agent in Clinical Development is a research paper published in Journal of Pharmacology and Experimental Therapeutics (2021). On theSindex it has a DataRank of 0. It has been cited 25 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access25 citations

Download PDF

Cite:

Linked data & code

nct doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)Impact (FWCI 1.11)OA: bronzeTopics (32)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (2)

Jaideep V. Thottassery,William B. Parker ORCID

Live enrichment

PubMed:34503994 PMC:PMC9164309 OpenAlex:https://openalex.org/W3197730637

NCATS NIH HHS

Grant: UL1 TR003096

NCI NIH HHS

Grant: N01 CO012400

NCRR NIH HHS

Grant: UL1 RR025777

NCI NIH HHS

Grant: P01 CA034200

FWCI

1.11

Citation Percentile

0.8%

Citation Trend

2022

2023

2024

2025

2026

bronzeLicense: https://www.elsevier.com/legal/tdmrep-license

journalhttps://jpet.aspetjournals.org/content/jpet/379/3/211.full.pdf

publisherhttps://jpet.aspetjournals.org/content/jpet/379/3/211.full.pdf

publisherhttps://api.elsevier.com/content/article/PII:S0022356524270889?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0022356524270889?httpAccept=text/plain

publisherhttps://syndication.highwire.org/content/doi/10.1124/jpet.121.000758

Fields of Study

Epigenetics and DNA MethylationAcute Lymphoblastic Leukemia researchHemoglobinopathies and Related DisordersAdministration, OralAnimalsBiological AvailabilityDNA (Cytosine-5-)-Methyltransferase 1DeoxycytidineDrug DevelopmentHumans

MeSH Terms

DNA (Cytosine-5-)-Methyltransferase 1Drug DevelopmentAdministration, OralAnimalsBiological AvailabilityDeoxycytidineHumans

Keywords

DecitabineDNA methyltransferaseAzacitidineDNMT1MethyltransferasePharmacologyDeoxycytidineChemistryDNA methylationBiochemistryBiologyMethylationDNACancerGenetics

Sustainable Development Goals

SDG 0: Good health and well-being

5-Aza-4′-thio-2′-deoxycytidine, a New Orally Bioavailable Nontoxic “Best-in-Class”: DNA Methyltransferase 1–Depleting Agent in Clinical Development

FAIR Checklist

Authors (2)

Funding (4 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)